Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Story summary
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Follow the latest stories from trusted publishers with concise summaries. Open the original source link for details.